An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor-positive early breast cancer.
The third-generation aromatase inhibitors (AIS) are largely replacing tamoxifen in the adjuvant treatment of early-stage breast cancer in postmenopausal women with hormone receptor-positive tumours. To date, multiple trials have been conducted comparing tamoxifen treatment with an AI, and all have demonstrated improved disease-free survival with AI treatment. Trials have included direct 5-year comparisons between tamoxifen and an AI, switching to an AI within 5 years after initial tamoxifen treatment, or extending treatment with an AI after 5 years of completed tamoxifen treatment. Some of these trials have been completed; others are ongoing; and head-to-head trial comparisons of individual AIS are also in progress. The present article summarizes the data obtained from various clinical trials of hormonal therapy for early breast cancer. It also reviews recent data so as to shed light on the current status of these therapies. The focus is on the efficacy of treatment with an AI. Toxicity is discussed in the second article in this supplement.
Verma
S
S
Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON. Sunil.verma@sunnybrook.ca
Sehdev
S
S
Joy
A
A
Madarnas
Y
Y
Younus
J
J
Roy
J A
JA